{"doi":"10.1111/jvim.16977","title":"The effect of ε-aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Background</jats:title>\n                    <jats:p>No treatment other than platelet administration is known to protect against spontaneous hemorrhage in thrombocytopenic dogs.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives</jats:title>\n                    <jats:p>Primary: determine if treatment with ε-aminocaproic acid (EACA) decreases the requirement for blood transfusions and improves outcome in dogs with severe thrombocytopenia. Secondary: find evidence of hyperfibrinolysis and determine the effect EACA administration on rapid (rTEG) and tissue plasminogen activator-spiked (tPA-rTEG) thromboelastography parameters.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals</jats:title>\n                    <jats:p>Twenty-seven dogs with severe thrombocytopenia were treated with EACA, and data from an additional 33 were obtained from the hospital database as historical control (HC) cohort.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>Single arm clinical trial with HCs. The EACA group dogs received EACA (100 mg/kg IV followed by a constant-rate infusion [CRI] of 400 mg/kg/24 hours). Thromboelastography before and during EACA infusion, hospitalization days, number of transfusions, and mortality were compared.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>No difference was found in number of transfusions per dog (median, interquartile range; 1, 0-2.5 vs 0.9, 0-2; P = .5) and hospitalization days (4, 4-6 vs 4.5, 3.75-6; P = .83) between HC and EACA groups, respectively, and no difference in survival was identified by log-rank analysis (P = .15). Maximum amplitude on both rTEG and tPA-rTEG increased after EACA administration (rTEG baseline: 23.6, 9.6-38.9; post-EACA: 27.3, 19.8-43.2; P &amp;lt; .001; tPA-rTEG baseline: 23, 10.9-37.2; post-EACA: 24.7, 16.7-44.8; P &amp;lt; .002).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance</jats:title>\n                    <jats:p>Although EACA increased clot strength, there was no effect on outcome. Treatment with EACA at this dosage cannot be recommended as a routine treatment but may be considered for dogs with severe ongoing hemorrhage.</jats:p>\n                  </jats:sec>","journal":"Journal of Veterinary Internal Medicine","year":2024,"id":618339,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":379757,"name":"Laura K. Ruterbories","orcid":null,"position":1,"is_corresponding":false},{"id":167318,"name":"Ian Handel","orcid":null,"position":2,"is_corresponding":false},{"id":1595087,"name":"Bernie Hansen","orcid":"0000-0002-5617-5825","position":3,"is_corresponding":false},{"id":1595081,"name":"Johanna Wolf","orcid":"0000-0002-7726-1845","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The effect of ε-aminocaproic acid on blood product requirement, outcome and thromboelastography parameters in severely thrombocytopenic dogs","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Background</jats:title>\n                    <jats:p>No treatment other than platelet administration is known to protect against spontaneous hemorrhage in thrombocytopenic dogs.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives</jats:title>\n                    <jats:p>Primary: determine if treatment with ε-aminocaproic acid (EACA) decreases the requirement for blood transfusions and improves outcome in dogs with severe thrombocytopenia. Secondary: find evidence of hyperfibrinolysis and determine the effect EACA administration on rapid (rTEG) and tissue plasminogen activator-spiked (tPA-rTEG) thromboelastography parameters.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals</jats:title>\n                    <jats:p>Twenty-seven dogs with severe thrombocytopenia were treated with EACA, and data from an additional 33 were obtained from the hospital database as historical control (HC) cohort.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>Single arm clinical trial with HCs. The EACA group dogs received EACA (100 mg/kg IV followed by a constant-rate infusion [CRI] of 400 mg/kg/24 hours). Thromboelastography before and during EACA infusion, hospitalization days, number of transfusions, and mortality were compared.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>No difference was found in number of transfusions per dog (median, interquartile range; 1, 0-2.5 vs 0.9, 0-2; P = .5) and hospitalization days (4, 4-6 vs 4.5, 3.75-6; P = .83) between HC and EACA groups, respectively, and no difference in survival was identified by log-rank analysis (P = .15). Maximum amplitude on both rTEG and tPA-rTEG increased after EACA administration (rTEG baseline: 23.6, 9.6-38.9; post-EACA: 27.3, 19.8-43.2; P &amp;lt; .001; tPA-rTEG baseline: 23, 10.9-37.2; post-EACA: 24.7, 16.7-44.8; P &amp;lt; .002).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance</jats:title>\n                    <jats:p>Although EACA increased clot strength, there was no effect on outcome. Treatment with EACA at this dosage cannot be recommended as a routine treatment but may be considered for dogs with severe ongoing hemorrhage.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38206934","pmcid":"PMC10937475","openalex_id":"https://openalex.org/W4390738733","authors":[],"funders":[],"total_grants":0,"fwci":1.2821,"citation_percentile":0.75961538,"influential_citations":0,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":2}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvim.16977","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvim.16977","host_type":"publisher"},{"url":"https://academic.oup.com/jvim/article-pdf/38/2/1013/66664915/jvim16977.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1111/jvim.16977","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38206934","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10937475","host_type":"repository"},{"url":"https://doaj.org/article/d484e5255afa4d0e986ce9e19e384e41","host_type":"repository"},{"url":"https://www.research.ed.ac.uk/files/397596303/JVIM-23-169.R3_Proof_hi.pdf","host_type":"repository"},{"url":"https://www.research.ed.ac.uk/en/publications/d15e91b6-7086-48e3-95f9-b8e014bffef9","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10937475/pdf/JVIM-38-1013.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10937475","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10937475?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Trauma, Hemostasis, Coagulopathy, Resuscitation","Hemostasis and retained surgical items","Blood transfusion and management","Humans","Dogs","Animals","Aminocaproic Acid","Thrombelastography","Tissue Plasminogen Activator","Hemorrhage","Thrombocytopenia","Antifibrinolytic Agents","Dog Diseases"],"mesh_terms":["Animals","Antifibrinolytic Agents","Dog Diseases","Dogs","Hemorrhage","Humans","Tissue Plasminogen Activator","Thrombelastography","Thrombocytopenia","Aminocaproic Acid"],"keywords":["Medicine","Thromboelastography","Hyperfibrinolysis","Interquartile range","Fibrinolysis","Anesthesia","Thrombelastography","Internal medicine","Surgery","Platelet","Platelets","Thrombocytopenia","Antifibrinolytics"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T04:07:01.597917Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}